Research Homepage
See all | 
News & stories
A common diabetes medication may slow memory decline in Alzheimer's disease
Researchers at Sunnybrook Research Institute and the University of Toronto found that the rate of memory decline was slower in people with Alzheimer’s disease taking a specific class of anti-diabetic drug, known as a dipeptidyl peptidase-4 (DPP4) inhibitor.
Two Sunnybrook-led studies awarded funding through the Ontario COVID-19 Rapid Research Fund
The $20-million fund will support researchers working to find ways to prevent, detect and treat COVID-19.
Sunnybrook researchers have developed a new way to detect hearing loss in blood
Scientists demonstrated a way to detect hearing disorders using a simple blood test
For trainees
Apply to be a SRI summer student, undergraduate student, graduate student or postdoctoral fellow
For researchers & administrators
Scientist profiles
We have more than 300 scientists
We have more than 300 scientists
Clinical research services
Help with trials and research ethics
Help with trials and research ethics
Core facilities
For internal and external use
For internal and external use
Leadership
Research executive committee
Research executive committee
SRI scientists in the news
How is poor sleep affecting the health of Ontarians?
Preliminary data show good quality slumber eludes many
Sleep disruptions related to changes in immune cells in brain and worse cognition: study
New research may help explain link between poor slumber and dementia
Trial launched on deep brain stimulation to treat severe alcohol-use disorder
Notable Canadian scientist is first participant
